Table 2.
Determinants of histidine-rich glycoprotein serum levels in lung cancer patients.
| Simple regression | Multiple regression | ||||
|---|---|---|---|---|---|
| β | p | β | p | R 2 | |
| Lung cancer patients | |||||
| K s | 0.09 | 0.27 | -0.13 | <0.001 | 0.19 |
| CLT | -0.41 | <0.001 | -0.42 | ||
| Fibrinogen | -0.18 | 0.03 | -0.15 | ||
| Stage IIIAB/LD lung cancer patients | |||||
| K s | -0.09 | 0.71 | -0.09 | 0.014 | 0.17 |
| CLT | -0.41 | 0.001 | -0.44 | ||
| Fibrinogen | -0.09 | 0.48 | -0.00 | ||
| Stage IV/ED lung cancer patients | |||||
| K s | 0.28 | 0.008 | 0.07 | <0.001 | 0.26 |
| CLT | -0.5 | <0.001 | -0.46 | ||
| Fibrinogen | -0.18 | 0.09 | -0.06 | ||
K s: fibrin clot permeability coefficient; CLT: clot lysis time; LD: limited disease; ED: extensive disease.